深圳新锐基因科技有限公司

Xinrui Gene is a biotechnology company headquartered in Shenzhen, China, dedicated to the development of innovative gene therapies. The company leverages its proprietary adeno-associated virus (AAV) vector platform to design and manufacture treatments for rare genetic disorders. Their primary focus areas include ophthalmology and metabolic diseases, where they aim to address significant unmet medical needs. Founded in 2021 by a team of experts in viral engineering, Xinrui Gene focuses on optimizing tissue-specific delivery and enhancing therapeutic efficacy. Their lead programs, such as XR-001 for Leber hereditary optic neuropathy, are currently in the pre-clinical development phase. The company has secured significant backing from prominent venture capital firms like Legend Capital and Qiming Venture Partners to advance its pipeline. Xinrui Gene's integrated approach combines vector discovery, process development, and clinical translation to accelerate the delivery of life-changing medicines.